Items in your cart Total: CAD 0.0

Please read and select which applies

You must meet below conditions to view this content

  1. I am over the age of 19.
  2. The products distributed are for medicinal purposes.

Continue With Google

Continue With Google

Forgot Password?.   forgot

Forgot Your Password ?

Dont't worry , Resetting Your Password is Easy,just tell us Registerd email address


Crohns Patients See 65% Remisson in Placebo/Cannabis Clinical Trial


Dragana Komnenov PhD

JANUARY 10, 2019

The huge success rate has nothing to do with changing inflammation in the gut, the most implicated culprit in Crohn’s flare ups. Researchers believe cannabis alters the gut biome to favor beneficial bacteria.

New data from the United European Gastroenterology conference in Vienna shows cannabis oil significantly improves symptoms of Crohn’s disease and the patients’ quality of life. Most interestingly, the mechanism does not appear to involve resolution of gut inflammation, but rather a change in gut biome.  This is in contrast to the previously hypothesized mode of action. Therefore, scientists rationalize cannabis’ therapeutic benefits come from the anti-inflammatory properties of cannabinoids.

In this randomized, placebo-controlled study, Israeli researchers observed 8 weeks of cannabis oil treatment. They found the treatment produced clinical remission in up to 65% of patients. This happened without downregulation of inflammation assessed endoscopically. This study includes 46 people with mild to moderate Crohn’s disease, randomized and receiving treatment consisting of 15% CBD and 4% THC in an oil form or placebo.

Gut Inflammation:

The study assesses gut inflammation endoscopically, and measures inflammatory markers in blood and stool samples. Most of the treatment group (15 out of 23 patients) after 8 weeks entered clinical remission compared to the placebo group (8 out of 23 patients). The question then remains: Which therapeutic principles other than anti-inflammatory could this cannabinoid-based treatment be operating on?

cannabis, medical cannabis, recreational cannabis, crohn's, gut bacteria, inflammation, anti-inflammatory, cannabinoids, research, legalization

The etiology of Crohn’ disease, and inflammatory bowel disease in general, divides into at least four factors: genes and genetic predisposition, external environment, microbiome (the ‘good’ bacteria living inside the gut) and the immune response. Doctors frequently hypothesisize that cannabis-based therapy affects the immune system. This study indicates this may not be the case.

However, the environment plays a role in the pathophysiology of Crohn’s disease. Therefore, because this study focuses on one geographical location (Israel), these findings don’t easily extrapolate to the rest of the world.

Furthermore, the interactions between genes and the environment further complicate the situation. It has been discovered that about 30 genetic mutations, or changes, are associated with Crohn’s disease. Among these, a small point mutation in the gene encoding one of the inflammatory mediator receptors, interleukin 23 (IL-23).

Additionally, the function of the anti-inflammatory mediator IL-10 has also been associated with Crohn’s disease. Given these mutations in the mediators which play prominent roles in regulation of inflammation, it is difficult to discern whether the study patients showed no reduction in inflammation in response to cannabis oil because of any possible mutations in the relevant genes since no genotyping data has been provided.

If They Ran The Study Longer, Would Inflammation Reduce further?

Finally, doctors are yet to determine whether the duration of the treatment affects inflammation outcomes. Its quite possible that 8 weeks may not be enough. Available evidence suggests that adaptive immunity and Th1 T cell recruitment is responsible for the aberrant inflammatory response in Crohn’s disease. This arm of the immunity is slower to develop (takes several days), and thus may take longer to resolve.

Furthermore, one of the effectors is IL-23 for which a genetic mutation has been associated with Crohn’s disease. This highlights the importance of knowing patients’ genotypes in clinical trials involving cannabis-based therapy. When we know these, different inflammation outcomes may occur.

Cannabis May Target Gut Biome Populations

Cannabis-based therapy could also target another aspect of Crohn’s disease etiology that doesn’t involve inflammation: the microbiome. There are approximately 1150 bacterial species in the gut that work together with our gastrointestinal system to process food and extract the nutrients. The association between Crohn’s disease and changes of the gut microbiome has already been established, with some studies demonstrating biodiversity reductions and others instability of the microbiome.

We are only at the forefront of the microbiome function research. Still, we know that specific bacterial species live in the healthy gut. Other species (called enterobacteria) represent an oversize sample in the Crohn’s disease gut.

cannabis, medical cannabis, recreational cannabis, Crohn's, gut bacteria, microbiome, enterobacterias, inflammation, anti-inflammatory, cannabinoids, cannabis oil, genetic mutations

In conclusion, cannabis oil could create new clinical outcomes. It would do this if we use it to restore the balance in the microbiome, rather than resolve inflammation. It could also be that CBD/THC oil sequentially acts on the various aspects of the disease’s etiology. This would mean resolving gut microbiome functions first, and eventually starting prolonged treatment (more than 8 weeks) to resolve inflammation.

In order to Post a comment - or

Related Articles



We can't solve your problem if you don't tell us about it!